PFS Improved in Frontline Squamous NSCLC with Atezolizumab Plus Chemo

PFS Improved in Frontline Squamous NSCLC with Atezolizumab Plus Chemo

2018-03-29 10:54:57

According to topline findings from the Phase 3 IMpower131 trial, the addition of atezolizumab (Tecentriq) to frontline carboplatin and nab-paclitaxel delayed progression or death compared with chemotherapy alone for patients with advanced squamous non–small cell lung cancer. These results were released by Genentech, the manufacturer of the anti–PD-L1 agent.

Source

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply